DID YOU KNOW? DTIC has over 3.5 million final reports on DoD funded research, development, test, and evaluation activities available to our registered users. Click
HERE to register or log in.
Accession Number:
AD1105402
Title:
89Zr-Trastuzumab-PET, Rapid Autopsies, and Patient Derived Xenografts to Determine the Extent of Clonal Evolution in Treatment Refractory HER2+ Gastric Cancer
Report Date:
2019-12-01
Abstract:
Trastuzumab, an FDA approved monoclonal antibody that binds to the extracellular domain of HER2, is the standard of care for these patients. However, after an initial response secondary resistance invariably ensues. The molecular basis of therapeutic resistance in HER2-positive EG cancer remains unknown and, until now, no other HER2-directed therapy has shown clinical efficacy in patients with trastuzumab refractory EG cancer.
Document Type:
Conference:
Journal:
Pages:
22
File Size:
3.29MB
W81XWH-16-1-0343
(W81XWH1610343);
Contracts:
Grants:
Distribution Statement:
Approved For Public Release
